Dataset Information

Phage display screening identifies a prostate specific antigen (PSA)^-/lo prostate cancer cell specific peptide to retard castration resistance of prostate cancer.

ABSTRACT: Patients with prostate cancer (PCa) will eventually progress to castrate-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT) treatment. Prostate-specific antigen (PSA)^-^/lo cells which harbor self-renewing long-term tumor-propagating cells that can be enriched using ALDH+CD44+α2β1+ and can initiate tumor development may represent a critical source of CRPC cells. Our purpose was to find a peptide that specifically targets PSA^-^/lo PCa cells to retard the development of CRPC. PSA⁺ and PSA^-^/lo cells were successfully separated from LNCaP xenograft tumors after prostate- PSAP-GFP vector infection and FACS. A variety of PSA^-^/lo cells specifically targeting peptide (named as "TA

SUBMITTER: Sui Y

PROVIDER: S-EPMC7844130 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Phage display screening identifies a prostate specific antigen (PSA)^-/lo prostate cancer cell specific peptide to retard castration resistance of prostate cancer.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Phage display screening identifies a prostate specific antigen (PSA)-/lo prostate cancer cell specific peptide to retard castration resistance of prostate cancer.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Phage display screening identifies a prostate specific antigen (PSA)^-/lo prostate cancer cell specific peptide to retard castration resistance of prostate cancer.